CSMYF Dividend: Cosmos Pharmaceutical Corp Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

CSMYF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	05/31/2025	05/31/2024	05/31/2023	05/31/2022	05/31/2021
Revenue	1,021,943	1,011,390	964,989	827,697	755,414	726,424
Revenue Growth (YoY)	4%	5%	17%	10%	4%	6%
Cost of Revenue	806,050	798,109	776,683	658,979	603,966	581,313
Gross Profit	215,893	213,281	188,306	168,718	151,448	145,111
Selling, General & Admin	175,424	152,430	138,536	122,807	107,756	99,163
Research & Development	--	--	--	--	--	--
Operating Expenses	175,424	172,877	156,805	138,590	121,652	111,964
Other Non Operating Income (Expenses)	2,837	2,962	2,853	2,962	3,065	2,691
Pretax Income	42,394	42,372	33,719	32,773	33,048	38,596
Income Tax Expense	11,387	11,393	9,265	8,975	9,892	11,439
Net Income	31,006	30,978	24,454	23,797	23,155	27,156
Net Income Growth	19%	27%	3%	3%	-15%	27%
Shares Outstanding (Diluted)	79.25	79.25	79.23	79.19	79.19	39.59
Shares Change (YoY)	0%	0%	0%	0%	100%	0%
EPS (Diluted)	391.2	390.85	308.6	300.47	292.36	685.77
EPS Growth	19%	27%	3%	3%	-56.99%	27%
Free Cash Flow	--	-859	-635	7,798	-11,303	1,809
Free Cash Flow Per Share	--	-10.83	-8.01	98.46	-142.71	45.68
Gross Margin	21.12%	21.08%	19.51%	20.38%	20.04%	19.97%
Operating Margin	3.96%	3.99%	3.26%	3.63%	3.94%	4.56%
Profit Margin	3.03%	3.06%	2.53%	2.87%	3.06%	3.73%
Free Cash Flow Margin	--	-0.08%	-0.06%	0.94%	-1.49%	0.24%
EBITDA	--	60,851	49,769	45,910	43,691	45,948
EBITDA Margin	--	6.01%	5.15%	5.54%	5.78%	6.32%
D&A For EBITDA	--	20,447	18,268	15,782	13,895	12,801
EBIT	40,469	40,404	31,501	30,128	29,796	33,147
EBIT Margin	3.96%	3.99%	3.26%	3.63%	3.94%	4.56%
Effective Tax Rate	26.85%	26.88%	27.47%	27.38%	29.93%	29.63%